Skip to main content
Journal of Pain Research logoLink to Journal of Pain Research
. 2026 Nov 2;19:631063. doi: 10.2147/JPR.S631063

Anti-Inflammatory and Analgesic Effects of Transdermal Tongluo Guzhining, a Traditional Chinese Medicine Patch, on Neuropathic Pain

Jiajun Xiang 1, Wenzhang Dai 2, Tengyun Xu 2, Kexin Cai 2, Yangxu Li 2, Hekun Zeng 2, Hui Ding 2, Yichun Sun 1, Yan Liang 3,✉, Hong Nie 2,✉
PMCID: PMC13742002  PMID: 42997405

Abstract

Background

Neuropathic pain (NP) is a chronic and debilitating condition characterized by persistent neuroinflammation, for which current therapeutic options offer limited efficacy and tolerability. Traditional Chinese medicine (TCM) provides a multi-targeted approach to treatment. Tongluo Guzhining Patch (TGP) has been used clinically for pain management; however, its effect on NP remains unclear.

Methods

This study combined network pharmacology with experimental validation to investigate the therapeutic potential of TGP. Computational analyses were performed to predict potential molecular targets and signaling pathways modulated by TGP. Subsequently, a chronic constriction injury (CCI) rat model was used to assess analgesic effects. Behavioral assessments, histopathological analyses, enzyme-linked immunosorbent assays (ELISA), quantitative polymerase chain reaction (qPCR), and Western blotting were conducted to evaluate inflammatory responses and the expression of key signaling molecules.

Results

Network pharmacology analysis identified inflammation-associated pathways, with the interleukin-17 (IL-17) signaling pathway among the enriched pathways potentially targeted by TGP. In vivo experiments showed that TGP significantly attenuated mechanical allodynia and reduced inflammatory cell infiltration in CCI rats, as confirmed by histological analysis. Furthermore, TGP markedly decreased the levels of pro-inflammatory cytokines IL-1β and IL-6 in dorsal root ganglia and spinal cord tissues. Additionally, both mRNA and protein expression levels of IL-17A, IL-17 receptor A (IL-17RA), IL-6, and tumor necrosis factor-alpha (TNF-α) were significantly downregulated following TGP treatment.

Conclusion

The findings indicate that TGP exerts potent anti-inflammatory and analgesic effects in a CCI-induced neuropathic pain model, likely through multi-target modulation of the IL-17-mediated inflammatory network. These results provide mechanistic insights supporting the therapeutic potential of TGP as an alternative treatment modality and underscore the IL-17 signaling pathway as a promising target for neuropathic pain intervention.

Keywords: neuropathic pain, Tongluo Guzhining patch, Traditional Chinese medicine, IL-17 signaling pathway, neuroinflammation network pharmacology

Introduction

Neuropathic pain is pain that is directly caused by damage or disease of the somatic sensory nervous system.1 It is a disabling condition that often comes with multiple complications, which further deteriorate the quality of life of the patients.2 Neuropathic pain affects an estimated 6.9–10% of the global population and is clinically characterized by spontaneous pain, hyperalgesia, and allodynia.3 In addition to sensory disturbances, neuropathic pain can alter mood and impair cognitive function, with depression and anxiety commonly observed in patients with severe disease.2,4 Given that the underlying mechanisms are not yet fully understood, many patients still experience refractory pain despite receiving existing treatments.5

The mechanisms underlying the onset and maintenance of neuropathic pain are complex, typically involving both central and peripheral nervous system components alongside nerve injury. A substantial body of evidence points to a key role for CNS glial cells and cytokines in mediating neuropathic pain.6–8 Astrocytes produce pro-inflammatory cytokines, including TNF-α, IL-1β, and IL-17, which in turn promote the initiation, progression, and maintenance of neuropathic pain.5,9 Pro-inflammatory cytokines, including TNF-α and IL-6, have been increasingly recognized as key mediators of injury-induced peripheral neuropathy and as drivers of the onset and progression of neuropathic pain.10,11 Conversely, other work has shown that anti-inflammatory cytokine activity reduces neuropathic pain.12 Furthermore, in the pathological pain model of rodents, IL-17 was found to be upregulated in both the peripheral and central nervous systems, and injecting the IL-17 antibody could alleviate pain sensitivity. The upregulation of IL-17 promotes neuroinflammation, enhances the excitability of sensory nerve endings neurons, and facilitates communication between glial cells and neurons in the spinal cord, thereby exacerbating pathological pain.13 These studies suggest the significance of cytokines TNF-α, IL-1β, and IL-17 in neuropathic pain.

Regrettably, the therapeutic options currently available for neuropathic pain tend to be poorly effective and carry a substantial risk of severe adverse reactions.14 Current treatment options for neuropathic pain include tricyclic antidepressants, gabapentin, pregabalin, and opioids. Even so, many patients—older adults in particular—remain vulnerable to the side effects of these drugs. The growing societal burden of neuropathic pain has led to considerable economic losses for both patients and national healthcare systems.15,16 Therefore, identifying more effective pharmacological options for neuropathic pain remains a pressing priority. Oral analgesic drugs may cause adverse effects in the gastrointestinal, cardiovascular, and renal systems. In comparison, transdermal therapeutic systems (TTS) provide a convenient and painless alternative by delivering drugs through the skin into local tissues or the systemic circulation while avoiding first-pass metabolism. As a result, therapeutic effects can often be achieved at lower doses than with systemic administration, which may reduce the risk of side effects and overdose.14 With the growing understanding of traditional herbal medicine, topical formulations of Chinese medicine—such as medicated plasters, patches, and ointments—have demonstrated beneficial therapeutic effects.17 In patch-based or other controlled-release systems, active components can be absorbed through the skin and act directly on joints and surrounding tissues, exerting local analgesic and anti-inflammatory effects while also improving microcirculation.18 Tongluo Guzhining Patch (TGP) is a traditional Chinese ethnomedicinal patch that helps promote blood circulation, dispel wind and dampness, and relieve pain by unblocking meridians. Its transdermal delivery reduces systemic exposure and associated risks compared to oral or injectable therapies. However, its efficacy against neuropathic pain and the underlying molecular mechanisms remain unclear.

Here we established a CCI model to evaluate the effects of TGP on neuropathic pain. Network pharmacology and transcriptomic analysis were used to identify potential targets. We found that transdermal application of this traditional patch alleviates neuropathic pain, an effect mediated in part through neuroimmune modulation and the IL-17 pathway. These results point to the therapeutic potential of topical herbal patches for neuropathic pain.

Materials and Methods

Network Pharmacology Analysis Data Preparation

Using keywords such as “Smilacis Chinae Rhizoma”, “Carthamus tinctorius L.”, “Aconiti Kusnezoffii Radix”, “Draconis Sanguis”, “Sinomenii Caulis”, “Hippocampus”, “Gonostegiae Herba”, “Pinelliae Rhizoma”, “Radix Chimonanthi Praecocis”, “Arisaematis Rhizoma”, “Radix Zanthoxyli Spinifolii”, “Fresh Mori Ramulus”, “Fresh Persicae Ramulus”, “Fresh Ulmi Ramulus”, “Fresh Salicis Ramulus” and “Fresh Sophorae Japonicae Ramulus” the active chemical constituents and their targets in TGP were retrieved from the TCMSP, PubChem, and Swiss Target Prediction databases. Concurrently, “neuropathic pain” was searched in the GeneCards and TTD databases, limited to Homo sapiens, to identify disease-related targets. After removing duplicates, a comprehensive set of neuropathic pain targets was compiled. Both drug- and disease-related target datasets were imported into InteractiVenn software to generate a Venn diagram, revealing overlapping targets shared by the therapeutic agents and the disease.

Construction of the Generate a Protein-Protein Interaction (PPI) Network

The targets associated with TGP and those related to neuropathic pain were uploaded to the Venny 2.1.0 tool to identify overlapping targets. The intersecting targets were then submitted to the STRING database to PPI network, with the species parameter restricted to Homo sapiens. The resulting PPI network was visualized using Cytoscape software, version 3.10.4.

Enrichment Analysis

After importing the intersection targets into the STRING database, the filter was set to “Homo sapiens” to build a PPI network. This network was scored, categorized, and analyzed for enrichment. Gene Ontology (GO) functional enrichment and pathway enrichment analyses using KEGG, Reactome, and WikiPathways databases were conducted on the top 20 highest-scoring targets.

Animals

Specific pathogen-free (SPF) female Sprague-Dawley rats, aged 6 to 8 weeks and weighing 190 to 210 grams, were obtained from Zhuhai BesTest Bio-Tech Co., Ltd. All experimental procedures involving animals were conducted in accordance with the guidelines approved by the Experimental Animal Ethics Committee of Zhuhai BesTest Bio-Tech Co., Ltd (Approval number: 2503001). The animals were housed in the Experimental Animal Center of Zhuhai BesTest Bio-Tech Co., Ltd under controlled environmental conditions, including a temperature of 24°C ± 1°C and a 12-hour light/dark cycle. Prior to the induction of the CCI model, the rats were acclimated for one week with ad libitum access to food and water. All animal procedures (including anesthesia with isoflurane, abdominal aorta blood collection, and euthanasia) were physically performed at their facilities, and ethical approval was obtained from their committee.

Euthanasia

At the end of the study, rats were deeply anesthetized with isoflurane (induction at 4–5%, maintenance at 1.5–2% in oxygen). Under deep anesthesia, blood was collected from the abdominal aorta. Immediately after blood collection, cervical dislocation was performed to ensure death. This procedure complied with the AVMA Guidelines for the Euthanasia of Animals (2020 edition) and GB/T 39760–2021 (Laboratory animals—Guidelines for euthanasia).

All animal experiments were performed in accordance with the ARRIVE guidelines (Animal Research: Reporting of In Vivo Experiments) and the National Research Council’s Guide for the Care and Use of Laboratory Animals (8th edition, 2011). In addition, all procedures complied with the relevant institutional and national guidelines and regulations for the care and use of laboratory animals in China, including the Regulations on the Administration of Laboratory Animals (State Council of China) and the Guidelines for the Humane Treatment of Laboratory Animals (Ministry of Science and Technology of China, 2006).

Construction of the CCI Rat Model and Drug Administration

Anesthesia and Surgical Preparation

Rats were anesthetized with isoflurane (RWD, China, Batch number:2025071401, induction at 4–5%, maintenance at 1.5–2% in oxygen). The depth of anesthesia was confirmed by the absence of the pedal withdrawal reflex. The right posterior thigh was shaved and disinfected with iodine solution.

CCI Surgery

Under aseptic conditions, a 1.5–2 cm longitudinal incision was made on the mid-right posterior thigh. The subcutaneous tissue and biceps femoris muscle was bluntly dissected to expose the sciatic nerve trunk. Proximal to the trifurcation (approximately 1 cm), four loose ligatures of 4–0 silk suture were placed around the nerve with approximately 1 mm spacing between each ligature, taking care to preserve the epineurial blood supply. The muscle and skin were closed in layers with 4–0 silk sutures. The surgical site was disinfected with iodine solution. Sham-operated rats underwent the identical procedure without nerve ligation. All animals received antibiotics for 3 consecutive days.

Model Validation and Grouping

Two weeks after surgery, mechanical withdrawal thresholds (MWT) were assessed using von Frey filaments. Rats exhibiting a stable decrease in MWT were considered successfully modeled. Animals with surgical complications (infection, severe motor impairment, or autotomy) were excluded. Successfully modeled rats were then randomly assigned to six groups (n = 6 per group) using a random number table: Sham, Model, Positive control (Lidocaine patch, topical, 63 mg/kg), Low-dose TGP (0.54 g/kg), Medium-dose TGP (1.08 g/kg), and High-dose TGP (2.16 g/kg). Randmization was performed by an investigator not involved in the surgical or behavioral procedures. The investigators performing behavioral assessments and data analysis were blinded to group allocation.

Postoperative Care

Animals were housed individually after surgery with soft bedding and free access to food and water. Body weight, wound healing, and general condition were monitored daily. Animals showing signs of infection or a body weight loss exceeding 20% were excluded according to pre-defined humane endpoint criteria.

Drug Administration

TGP is a topical Patch preparation with a clinical dosage of 6 g per Patch. Based on the clinical dosage and dose conversion, the medium dose from the preliminary study (0.54 g/kg) was selected as the low dose for the formal experiment. Medium and high doses were set at 1.08 g/kg and 2.16 g/kg, respectively. The Patch was applied directly to the shaved skin overlying the affected knee. Except for the Sham and Model groups, All groups were administered a single dose once daily for a duration of seven consecutive days. TGP is a commercially available traditional Chinese medicine patch (approval number: National Medicine Approval No. Z20025964; manufacturer: Sinopharm Group Tongjitang (Guizhou) Pharmaceutical Co., Ltd., Guiyang, China). Each patch contains 6 grams of herbal paste. The Patch consists of a medicated adhesive layer and a protective backing film, with a total application area of approximately 7.5×5.5 cm (Batch number:20250101).

Behavioral Assessment

MWT were assessed using von Frey filaments on days 1, 4, 7, 10, and 14 following the establishment of the CCI model, as well as on days 1, 3, 5, and 7 after drug administration. Baseline MWT measurements were obtained prior to model induction. Before testing, rats were acclimated to the experimental environment for 30 minutes. A series of von Frey filaments (0.6, 1, 1.4, 2, 4, 6, 8, 10, and 15 g; Stoelting, Wood Dale, IL, USA) were applied perpendicularly to the lateral plantar surface of the right hind paw with enough force to cause slight bending, each filament held in place for approximately 2 to 3 seconds. A positive response was defined as rapid paw withdrawal or licking.19

ELISA

Following the final administration, blood samples were collected from the abdominal aorta of the rats. The blood was allowed to stand at room temperature before being centrifuged at 4500 rpm for 10 minutes. Subsequently, the supernatant was carefully harvested, and the concentrations of IL-6 (Cat. No. JL20896), TNF-α (Cat. No. JL13202), and PGE2 (Cat. No. JL12640) in the serum of each experimental group were quantitatively measured according to the manufacturer’s protocols for the ELISA kits.

Hematoxylin and Eosin Staining

Dorsal root ganglia (DRG) and spinal cord segments from lumbar levels L3 to L5 were harvested. The collected tissues were fixed in 4% paraformaldehyde and subsequently embedded in paraffin. The paraffin-embedded DRG and SC samples were sectioned into 5 μm-thick slices and incubated at 60°C for 20 minutes. The sections were then immersed in xylene for 20 minutes to remove the paraffin, followed by ethanol washes. Next, the sections were stained with hematoxylin for 3 minutes, rinsed, and counterstained with eosin. Finally, the stained sections were examined under an optical microscope and digitized using a pathological slide scanner for further analysis.

Transcriptome Sequencing and Analysis

RNA was extracted from rat spinal cord samples using TRIzol reagent. To analyze the transcriptome, mRNA was first isolated from the total RNA. First-strand cDNA was synthesized from the mRNA using random primers and reverse transcriptase. Second-strand synthesis was then performed to generate stable double-stranded cDNA. The double-stranded cDNA products underwent end repair using an EndRepair Mix, followed by adapter ligation. After purification and size selection of the adapter-ligated products, PCR amplification was conducted, and the resulting libraries were purified again. All libraries were sequenced on an Illumina NovaSeq instrument using the NovaSeq Reagent Kit. Raw data normalization was performed on the Tsingke platform, followed by statistical modeling for data analysis. Differential expression analysis was conducted with DESeq2 (|log2 FC| ≥ 1, adj. *p < 0.05). GO and KEGG enrichment analyses were performed using clusterProfiler (adj. *p < 0.05).

Western Blot

Rat spinal cord samples was harvested and immediately immersed in TRIzol lysis buffer supplemented with protease and phosphatase inhibitors. Protein extraction was performed strictly according to the manufacturer’s TRIzol protocol. Protein concentrations were quantified using a bicinchoninic acid (BCA) assay kit. Subsequently, sample loading buffer was added to the protein extracts at a ratio of 4:1, and the mixtures were denatured by heating in a boiling water bath for 10 minutes. Proteins were then separated via SDS-PAGE and transferred onto polyvinylidene difluoride (PVDF) membranes. Membranes were blocked with 5% skim milk or bovine serum albumin (BSA) for 2 hours, followed by three washes with phosphate-buffered saline containing Tween-20 (PBST). The membranes were incubated overnight at 4°C with primary antibodies targeting IL-17 (anti-IL-17A: Affinity Biosciences, Cat. No: DF6127, 1:1500), IL-17RA (anti-IL-17RA, Affinity Biosciences, Cat. No: DF3602, 1:1000), IL-6 (anti-IL-6, Affinity Biosciences, Cat. No: DF6087, 1:1000), TNF-α (anti-TNF-α, Affinity Biosciences, Cat. No: AF7014, 1:500), and GAPDH. After washing with PBST, membranes were incubated with appropriate secondary antibodies at room temperature for 2 hours. Immunoreactive bands were visualized using a gel imaging system, and densitometric analysis was conducted using Image J software.

Real-Time Fluorescent Quantitative Polymerase Chain Reaction (RT-qPCR)

Total RNA was isolated from rat spinal cord samples using TRIzol lysis buffer, with 1000 μL of TRIzol reagent applied per 100 mg of tissue, following the established protocol. RNA extraction was performed meticulously according to the manufacturer’s instructions for TRIzol. After RNA quantification, reverse transcription was conducted following the reagent kit guidelines. RT-qPCR amplification targeted IL-17, IL-17RA, IL-6, and TNF-α. The thermal cycling parameters were set as follows: an initial denaturation at 95°C for 30 seconds, followed by 40 amplification cycles, each consisting of 95°C for 5 seconds, 60°C for 30 seconds, and 95°C for 15 seconds. Relative gene expression levels were normalized against GAPDH. Finally, the resulting data were processed for analysis. The primer sequences are provided in Table S1.

Statistical Analyses

All data were prepared with Prism software, version 9 (GraphPad Software, San Diego, CA, US) and statistical differences were analyzed using One way ANOVA and two-way repeated-measures ANOVA, followed by Dunnett’s post hoc tests for multiple comparisons. The values were expressed as the mean ± SEM, and *p < 0.05 was deemed to be statistically significant.

Results

Network Pharmacology Analysis

As illustrated in Figure 1A, after removing duplicate entries, a total of 789 targets associated with TGP and 818 targets related to NPP were identified, resulting in 283 overlapping targets. These overlapping targets were then submitted to the STRING database to construct a PPI network, as shown in Figure 1B. Key targets, including IL-6, GAPDH, TNF, AKT1, IL-1B, ALB, STAT3, EGFR, CASP3, and JUN, were identified from this network, as presented in Figure 1B. Additionally, a traditional Chinese medicine–component–target network was established to assess potential bioactive components, as illustrated in Figure 1C. GO and KEGG enrichment analyses indicated that the therapeutic effects of TGP on neuropathic pain may be mediated through modulation of signaling pathways such as IL-4, IL-13, PI3K/AKT, glioblastoma, oncostatin M, and CKAP4 pathways (Figure 1D–I).

Figure 1.

Network pharmacology analysis of TGP in CCI treatment with Venn, PPI and enrichment analyses. A Venn diagram shows 789 targets for Tongluo Guzhining, 818 for CCI, with 283 overlapping. A PPI network displays overlapping targets, highlighting key targets like IL-6, GAPDH, TNF, AKT1, IL-1B, ALB, STAT3, EGFR, CASP3 and JUN. A herb to compound to target network is shown with bar plots ranking top compounds and targets by degree. Gene Ontology biological process enrichment analysis includes sensory perception, response to stimulus and regulation of signaling. Cellular component enrichment analysis highlights membrane and organelle parts. Molecular function enrichment analysis covers transporter and binding activities. KEGG pathway enrichment analysis involves IL-4, IL-13 and PI3K/AKT pathways. Reactome pathway enrichment analysis includes cytokine signaling and immune system pathways. WikiPathways enrichment analysis features GPVI-mediated activation and IL-4 signaling pathways.

Network pharmacology analysis of TGP in the treatment of CCI. (A) Venn diagram showing the intersection targets between TGP-related targets and CCI-related targets. (B) PPI network of the overlapping targets and screening of core hub targets based on topological analysis. (C) Herb–compound–target network of TGP. The bar plots on the right present the top active compounds and key targets ranked by degree value in the network. (D) Gene Ontology (GO) biological process (BP) enrichment analysis of the overlapping targets. (E) GO cellular component (CC) enrichment analysis of the overlapping targets. (F) GO molecular function (MF) enrichment analysis of the overlapping targets. (G) Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of the overlapping targets. (H) Reactome pathway enrichment analysis of the overlapping targets. (I) WikiPathways enrichment analysis of the overlapping targets.

TGP Ameliorates Inflammation and Pain in CCI Rats

As illustrated in Figures 2A and B, following ligation of the rat sciatic nerve, the mechanical pain threshold typically stabilizes between postoperative days 10 and 14, with pain sensitivity peaking on day 14. A significant difference in pain threshold was observed between the model group and the sham-operated control group. Consequently, pharmacological intervention was initiated on postoperative day 15. On the third day of treatment, both the high-dose TGP group and the positive control drug group demonstrated a significant reduction in mechanical pain in rats, with the high-dose group showing superior efficacy compared to the positive control (Figure 2C). By the fifth day, the analgesic effects of the high-dose group and the positive control drug were comparable. The decreased analgesic efficacy of lidocaine observed on day 7 may reflect the natural progression of neuropathic pain in the CCI model or changes in lidocaine permeability over time, rather than the development of pharmacological tolerance. Following a continuous 7-day treatment regimen, TGP markedly decreased the serum concentrations of TNF-α, IL-6, and PGE2 in rats (p< 0.01); in contrast, the positive control drug significantly reduced the levels of TNF-α and IL-6 but did not produce a statistically significant effect on PGE2 levels (Figure 2D–F). In addition, no significant differences in liver or kidney indices were observed among the groups (Figures S1 and S2).

Figure 2.

A multi panel figure with 2 line graphs, 3 bar charts and 1 timeline about CCI and TGP outcomes. Image A shows a timeline for model construction and drug administration from Day -1 to 22, with key events like shaving on Day -1 and Von Frey tests on circled days. Image B is a line graph comparing Sham and Model groups over time, showing mechanical withdrawal thresholds. Sham remains stable around 14-15g, while Model decreases from 14g to 2g by Day 14. Image C presents another line graph with multiple treatments: Sham stays flat at 15g, Model remains low, Lidocaine increases from 2g to 9g by Day 5 and various plaster doses show different trends. Image D is a bar chart of TNF alpha levels, with Sham at 190 picograms per milliliter, Model at 280 picograms per milliliter and other treatments ranging from 100 to 150 picograms per milliliter. Image E shows IL-6 levels, with Sham at 170 picograms per milliliter, Model at 270 picograms per milliliter and other treatments between 130 and 145 picograms per milliliter. Image F displays PGE2 levels, with Sham at 3200 picograms per milliliter, Model at 4800 picograms per milliliter and other treatments decreasing from 3300 to 1300 picograms per milliliter.

Therapeutic effects of TGP on CCI-induced neuropathic pain and inflammatory responses in rats. (A) Experimental timeline for CCI model establishment and drug administration. (B) Time course of changes in the 50% mechanical withdrawal thresholds (MWT) in sham-operated and CCI model groups during model establishment. (C) Effects of low-, medium-, and high-dose TGP, as well as lidocaine (positive control), on MWT in CCI rats. (D–F) Serum levels of TNF-α (D), IL-6 (E), and PGE2 (F) in CCI rats following TGP treatment. Data are presented as mean ± SEM. n = 3–6 per group. *P < 0.05, **P < 0.01, and ***P < 0.001 vs the model group.

TGP Ameliorates Inflammatory Cell Infiltration in the DRG and Spinal Cord of CCI Rats

TGP treatment reduced inflammatory cell infiltration and cellular vacuolization in both the spinal cord and DRG of CCI rats. As shown in Figure 3A (spinal cord) and Figure 3B (DRG), H&E staining revealed fewer infiltrating inflammatory cells in the TGP-treated groups compared with the Model group.

Figure 3.

Micrograph with parts A & B: 6 stained sections labeled Sham, Model, Lidocaine 63mg/kg, TGP 0.54, 1.08, 2.16g/kg.

Histopathological evaluation of spinal cord and dorsal root ganglion tissues in CCI rats following TGP treatment. (A) Representative hematoxylin and eosin (H&E) staining images of spinal cord tissues from different experimental groups. (B) Representative H&E staining images of DRG tissues from different experimental groups (n = 3).

Transcriptomic Analysis of TGP-Mediated Amelioration in CCI Rats

The transcriptomic PCA results reveal significant differences among the Sham group, TGP group, and Model group samples (Figure 4A–D). Using selection criteria of FC > 2 or < 0.5 combined with a significance threshold of *P < 0.05, a total of 715 DEGs were identified in the comparison between the Sham and Model groups, including 335 upregulated and 380 downregulated genes. Additionally, 355 DEGs were detected in the TGP group relative to the Model group, comprising 233 upregulated and 112 downregulated genes. Transcriptomic analysis, as shown in Figures 4E and F, reveals that the GO functions associated with the therapeutic effects of TGP on CCI involve several biological processes, including the regulation of cell population proliferation, response to glucocorticoids, calcium ion binding, and chemokine-mediated signaling pathways. The relevant cellular components identified include astrocyte projections, the extracellular region, and glial cell projections. Additionally, molecular functions such as calcium ion binding, glutathione transferase activity, and chemokine activity are implicated. Furthermore, KEGG pathway enrichment analysis indicates significant involvement in pathways related to drug metabolism via cytochrome P450, the IL-17 signaling pathway, cytokine receptor interactions, metabolism of xenobiotics by cytochrome P450, retrograde endocannabinoid signaling, chemokine signaling pathway, Ras signaling pathway, FcεRI signaling pathway, MAPK signaling pathway, linoleic acid metabolism, and glycolysis/gluconeogenesis.

Figure 4.

A multi plot figure with a scatter plot, bar chart, two volcano plots, a bar chart and bubble plot. The image A showing a scatter plot titled, PCA analysis. The x axis label is, PC1 with percent 87.56 percent, unit not shown. The y axis label is, PC2 with percent 9.31 percent, unit not shown. Three groups are shown in the legend: Model, Sham and TL. Points are labeled Model1, Model2, Model3 clustered near x about negative 15 to negative 5 and y about negative 3 to 2. Sham1, Sham2, Sham3 cluster near x about negative 10 to 0 and y about 8 to 11. TL1, TL2, TL3 cluster near x about negative 10 to 0 and y about negative 10 to negative 7. A point labeled A4 lies near x about 38 and y about 0, connected within the TL polygon. The image B showing a grouped bar chart titled, Differential statistics. The x axis label is not shown, with categories ShamvsModel and TLvsModel, unit not shown. The y axis label is, Number of DEGs, unit not shown, ranging from 0 to 400. Legend shows up and down. ShamvsModel bars: up 335, down 380. TLvsModel bars: up 233, down 112. The image C showing a volcano scatter plot titled, ShamvsModel.volcano. The x axis label is, log2FC, unit not shown, ranging about negative 8 to 8. The y axis label is, minus log10 adjusted p value, unit not shown, ranging about 0 to 16. A legend titled, significant, lists up with 335, down with 380 and no with 0. Points form a central wedge near x 0 with many points below y 2, with red points on positive log2FC and blue points on negative log2FC. The image D showing a volcano scatter plot titled, TLvsModel.volcano. The x axis label is, log2FC, unit not shown, ranging about negative 6 to 6. The y axis label is, minus log10 adjusted p value, unit not shown, ranging about 0 to 6.5. A legend titled, significant, lists up with 233, down with 112 and no with 0. Red points concentrate on positive log2FC and blue points on negative log2FC, with the highest points near y about 6. The image E showing a bar chart titled, GO enrichment analysis. The x axis label is, GO term, unit not shown. The y axis label is, minus log10 p value, unit not shown, ranging about 0 to 1.8. A legend lists BP, CC and MF. Multiple bars are shown across the three groups of terms, with the tallest bar near 1.7 and several bars between about 0.4 and 1.4. The image F showing a bubble plot titled, KEGG enrichment analysis. The x axis label is, Rich Factor, unit not shown, ranging about 0.02 to 0.12. The y axis label is, KEGG pathway, unit not shown, listing pathways including Drug metabolism cytochrome P450, IL 17 signaling pathway, Cytokine receptor interaction, Metabolism of xenobiotics by cytochrome P450, Retrograde endocannabinoid signaling, Chemokine signaling pathway, Ras signaling pathway, Fc epsilon RI signaling pathway, MAPK signaling pathway, Linoleic acid metabolism and Glycolysis Gluconeogenesis. A color scale labeled Padjust ranges from 0.000 to 0.040, unit not shown. Bubble size legend labeled Number ranges from 2 to 8, unit not shown. The largest rich factor point is near 0.11 for Drug metabolism cytochrome P450 and several points cluster between 0.03 and 0.07 across multiple pathways.

Multivariate and differential feature analysis of experimental groups. (A) Principal component analysis (PCA) showing the clustering of samples from three groups (Model, Treatment, Control; n = 3 per group), indicating distinct separation among groups. (B) Number of significantly up-regulated and down-regulated features in each comparison (Model vs Control, Treatment vs Model), determined using |log2FC| > 1 and adjusted p < 0.05. (C) Volcano plot of differential features between Model and Control groups. Red and blue dots represent significantly up- and down-regulated features, respectively. (D) MA plot displaying fold changes versus mean expression, highlighting significantly altered features. (E) Bar plot of top enriched functional categories based on differential features across groups. (F) KEGG pathway enrichment analysis.

Effects of TGP on Gene and Protein Expression Profiles in Rat Spinal Cord with CCI

RT-qPCR analysis demonstrated that administration of TGP at low, medium, and high doses significantly reduced the mRNA expression levels of IL-17A, IL-17RA, IL-6, and TNF-α (Figure 5A–D, p< 0.05 or p< 0.01). Notably, the downregulation of IL-17RA, IL-6, and TNF-α was particularly pronounced, reaching a high level of statistical significance (p< 0.001). WB results indicate that, compared to the Model group, all dosage groups of TGP significantly reduced the protein expression levels of IL-17A, IL-17RA, IL-6, and TNF-α to varying degrees (Figure 5E–I, p< 0.05 or p< 0.01). Specifically, low, medium, and high doses all significantly decreased IL-6 protein levels (p< 0.05). The medium and high dose groups notably downregulated IL-17A and TNF-α protein levels (p< 0.01).

Figure 5.

An infographic of cytokine mRNA and protein levels: Model higher, TGP doses lower toward Sham. Images A-I show bar charts and Western blot results comparing mRNA and protein expression levels across different groups: Sham, Model, Lidocaine and TGP doses (0.54g/kg, 1.08g/kg, 2.16g/kg). In all charts, the Model group shows higher expression than Sham, while Lidocaine and TGP groups show lower expression than Model. Specific measurements include IL-17A, IL-17RA, IL-6, TNF-alpha and their ratios to GAPDH. Western blot bands for IL-17A, IL-17RA, TNF-alpha and IL-6 are stronger in Model than Sham and weaker in Lidocaine and TGP lanes. Data are presented as mean plus or minus SEM (n equal 3), with significance indicated by asterisks: *p less than 0.05, **p less than 0.01, ***p less than 0.001 vs Model.

Effects of TGP treatment on inflammatory cytokine expression and protein levels. (A–D) Relative mRNA expression levels of IL-17A (A), IL-17RA (B), IL-6 (C), TNF-α (D). (E and F) Quantification of Western blot bands for IL-17A (E) and IL-17RA (F). (G) Expression of IL-17A, IL-17RA, TNF-α and IL-6 proteins. (H and I) Quantification of Western blot bands for IL-6 (H) and TNF-α (I). Data are presented as mean ± SEM (n = 3). *p < 0.05, **p < 0.01, ***p < 0.001 vs the Model group.

Discussion

Recent evidence from systematic reviews and updated guidelines indicates that tricyclic antidepressants, serotonin-noradrenaline reuptake inhibitors, and gabapentinoids remain the first-line pharmacological options for neuropathic pain. For localised neuropathic pain, topical 8% capsaicin patches and 5% lidocaine Patchs are now established as second-line treatments, both with favourable safety profiles.20,21 Nevertheless, the overall efficacy of currently available therapies remains modest, underscoring a clear unmet need for developing new therapeutic strategies.

The analgesic effects of TCM, characterized by multicomponent and multitarget mechanisms, are well documented, with a notable advantage of low adverse effect burden.22,23 Pharmacological studies have further revealed that TCM alleviates neuropathic pain through suppressing inflammatory responses, modulating neuronal excitability, and regulating ion channels.24–26 Among these approaches, topical TCM patches offer a non-invasive drug delivery route that effectively bypasses gastrointestinal irritation and first-pass metabolism associated with oral administration, while also providing sustained and continuous drug release for pain relief. The TGP, used in the present study, is a classic TCM formula. It addresses the shortcomings of conventional patches, such as short bioavailability duration and insufficient analgesic efficacy.

Network pharmacology provided the initial clue to the therapeutic potential of TGP against neuropathic pain, suggesting that its analgesic effect might involve the HIF-1, PI3K/AKT, and interleukin-related signaling pathways along with certain targets within these networks. It is important to acknowledge that the KEGG enrichment analysis identified multiple pathways beyond IL-17 signaling, including the MAPK, chemokine, and drug metabolism (cytochrome P450) pathways. These pathways were not further explored in the current study. IL-17 signaling was prioritized because it emerged as a central node in our protein-protein interaction (PPI) network analysis and is well known for its involvement in neuroinflammation and pathological pain. Nevertheless, the potential significance of these other pathways should not be overlooked, and their roles in mediating the analgesic and anti-inflammatory effects of TGP warrant further investigation. Guided by this prediction, we evaluated TGP in a rat model of CCI. Measurements of paw withdrawal thresholds to mechanical stimulation revealed that TGP increased these thresholds, confirming a clear analgesic action.

Inflammation is far from a passive bystander in neuropathic pain. Under neuropathic conditions, immune cells including neutrophils, macrophages, and T cells infiltrate injured tissues.27 Once activated, these cells generate large quantities of inflammatory mediators such as TNF, IL-1β, and IL-6.28 These mediators in turn promote neuroimmune activation and trigger pain by binding to receptors on nociceptors.29,30 In our experiments, TGP substantially reduced the release of TNF-α and IL-6 in the serum of CCI rats. HE staining further showed fewer inflammatory cells and less pronounced inflammatory infiltration following TGP treatment. These results fit well with the network pharmacology prediction, in which TNF-αand IL-6 appeared as core nodes in the PPI network.

These observations are particularly relevant due to the synergistic amplification characteristic of the IL-17 signaling pathway and the cytokines IL-6 and TNF-α.31 Specifically, IL-17A binds to its receptor IL-17RA, activating downstream signaling pathways such as NF-κB and MAPK, which in turn increase the production and release of IL-6 and TNF-α by target cells. At the same time, IL-6 and TNF-α promote the differentiation of Th17 cells and the generation of IL-17A, creating a positive feedback loop that intensifies inflammatory responses.32,33 In neuropathic pain models like CCI, this feedback loop becomes overactive, leading to higher levels of IL-17A, IL-6, and TNF-α in the spinal cord and DRG.33 The resulting increase in these mediators intensifies neuroinflammation and the transmission of nociceptive signal.

Treatment with total TGP reduced both mRNA and protein expression levels of IL-17A, IL-17RA, IL-6, and TNF-α. Nevertheless, the magnitude of downregulation was not uniformly proportional across these molecular levels. For example, reductions in protein expression for IL-17RA did not fully parallel the decreases observed at the mRNA level. Such discrepancies are frequently encountered and may be attributed to diverse post-transcriptional regulatory mechanisms, including variations in mRNA stability, translational efficiency, and rates of protein degradation.34,35 Moreover, cytokines such as IL-6 and TNF-α are subject to intricate post-translational modifications and feedback regulatory processes, which can further dissociate mRNA abundance from protein expression.36 Our data demonstrate that TGP treatment is associated with reduced expression of IL-17A, IL-17RA, IL-6, and TNF-α, suggesting that TGP may attenuate this positive feedback loop. However, since the present study exclusively measured expression changes without directly examining the dynamics of the feedback mechanism, a definitive causal relationship between IL-17 pathway inhibition and the analgesic effects of TGP cannot be established.

However, several limitations of this study should be acknowledged. First, regarding the animal model, we employed the CCI model, which replicates some but not all features of clinical neuropathic pain. The CCI model primarily reflects peripheral nerve injury-induced pain and may not fully capture the complexity of central neuropathic pain or painful diabetic neuropathy in humans.37 Second, the treatment duration was relatively short (7 days), which is insufficient to evaluate the long-term efficacy of TGP. Whether the analgesic effects are sustained over prolonged administration remains to be determined. Third, the sample size was relatively small, a larger sample size would enhance the statistical power and strengthen confidence in the robustness of the findings.38 Fourth, regarding clinical translation, although transdermal TGP showed promising analgesic and anti-inflammatory effects in rats, transdermal absorption is influenced by skin barrier properties and formulation factors, which may affect reproducibility across different patch preparations. In addition, the species differences in drug metabolism, immune responses, and pain pathways could affect the translational potential of TGP. Moreover, our study did not include mechanistic experiments such as pathway-specific inhibitors, IL-17 knockout models, or functional rescue experiments, which are necessary to definitively establish that the analgesic effects are specifically mediated through IL-17 signaling inhibition. Future studies addressing these limitations will help clarify the clinical utility of TGP for neuropathic pain.39

Conclusion

The current study shows that TGP treatment can relieve mechanical hyperalgesia and lessen inflammatory cell infiltration in the CCI rat model. Additionally, it significantly lowers the mRNA and protein levels of IL-17A, IL-17RA, IL-6, and TNF-α. Importantly, these effects vary according to the dosage. In summary, the primary mechanisms behind TGP’s anti-inflammatory and pain-relieving properties involve blocking the IL-17 signaling pathway and its downstream cytokines, IL-6 and TNF-α. Collectively, these results underscore the therapeutic potential of transdermal TGP for neuropathic pain management and highlight the need for continued mechanistic and translational research.

Acknowledgments

This research was supported by the National Natural Science Foundation of China (No. 818611380).

Data Sharing Statement

All data generated or analyzed during this study are included in this manuscript and its supplementary information flies.

Ethics Approval and Consent to Participate

All the animal experiments were approved by the Experimental Animal Ethics Committee of Zhuhai BesTest Bio-Tech Co., Ltd (Approval number: 2503001).

Author Contributions

Jiajun Xiang: Conceptualization, Data curation, Formal analysis, Writing – original draft, Writing – review & editing. Wenzhang Dai and Tengyun Xu: Conceptualization, Investigation, Formal analysis, Writing – original draft, Writing – review & editing. Kexin Cai and Yangxu Li: Methodology, Validation, Investigation. Hekun Zeng and Hui Ding: Investigation, Resources, Supervision. Yichun Sun, Yan Liang, and Hong Nie: Funding acquisition, Project administration, Conceptualization, Writing – review & editing. All authors have read and approved the final version of the manuscript. All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Disclosure

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

  • 1.Malcangio M, Sideris-Lampretsas G. How microglia contribute to the induction and maintenance of neuropathic pain. Nat Rev Neurosci. 2025;26(5):263–14. doi: 10.1038/s41583-025-00914-5. [DOI] [PubMed] [Google Scholar]
  • 2.Bushnell MC, Ceko M, Low LA. Cognitive and emotional control of pain and its disruption in chronic pain. Nat Rev Neurosci. 2013;14(7):502–511. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Tsuda M, Masuda T, Kohno K. Microglial diversity in neuropathic pain. Trends Neurosci. 2023;46(7):597–610. [DOI] [PubMed] [Google Scholar]
  • 4.Borgonetti V, Morozzi M, Galeotti N. Neuroinflammation evoked mechanisms for neuropathic itch in the spared nerve injury mouse model of neuropathic pain. Neuropharmacology. 2024;259:110120. doi: 10.1016/j.neuropharm.2024.110120. [DOI] [PubMed] [Google Scholar]
  • 5.Sun JL, Dai WJ, Shen XY, Lü N, Zhang YQ. Interleukin-17 is involved in neuropathic pain and spinal synapse plasticity on mice. J Neuroimmunol. 2023;377:578068. doi: 10.1016/j.jneuroim.2023.578068. [DOI] [PubMed] [Google Scholar]
  • 6.Watkins LR, Maier SF. Beyond neurons: evidence that immune and glial cells contribute to pathological pain states. Physiol Rev. 2002;82(4):981–1011. doi: 10.1152/physrev.00011.2002. [DOI] [PubMed] [Google Scholar]
  • 7.Hung AL, Lim M, Doshi TL. Targeting cytokines for treatment of neuropathic pain. Scand J Pain. 2017;17:287–293. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Luo H, Liu HZ, Zhang WW, et al. Interleukin-17 regulates neuron-glial communications, synaptic transmission, and neuropathic pain after chemotherapy. Cell Rep. 2019;29(8):2384–2397.e2385. doi: 10.1016/j.celrep.2019.10.085. [DOI] [PubMed] [Google Scholar]
  • 9.Schäfers M, Svensson CI, Sommer C, Sorkin LS. Tumor necrosis factor-alpha induces mechanical allodynia after spinal nerve ligation by activation of p38 MAPK in primary sensory neurons. J Neurosci. 2003;23(7):2517–2521 10.1523/JNEUROSCI.23-07-02517.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Eliav E, Benoliel R, Herzberg U, Kalladka M, Tal M. The role of IL-6 and IL-1beta in painful perineural inflammatory neuritis. Brain Behav Immun. 2009;23(4):474–484 10.1016/j.bbi.2009.01.012. [DOI] [PubMed] [Google Scholar]
  • 11.Stoll G, Jander S, Myers RR. Degeneration and regeneration of the peripheral nervous system: from Augustus Waller’s observations to neuroinflammation. J Peripheral Nervous Syst. 2002;7(1):13–27 10.1046/j.1529-8027.2002.02002.x. [DOI] [PubMed] [Google Scholar]
  • 12.Noma N, Khan J, Chen IF, et al. Interleukin-17 levels in rat models of nerve damage and neuropathic pain. Neurosci Lett. 2011;493(3):86–91 10.1016/j.neulet.2011.01.079. [DOI] [PubMed] [Google Scholar]
  • 13.Gao SJ, Liu L, Li DY, et al. Interleukin-17: a putative novel pharmacological target for pathological pain. Curr Neuropharmacol. 2024;22(2):204–216. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Göntér K, László S, Tékus V, et al. New generation capsaicin-diclofenac containing, silicon-based transdermal patch provides prolonged analgesic effect in acute and chronic pain models. Eur J Pharm Sci. 2025;207:107035 10.1016/j.ejps.2025.107035. [DOI] [PubMed] [Google Scholar]
  • 15.Patel MK, Kaye AD, Urman RD. Tanezumab: therapy targeting nerve growth factor in pain pathogenesis. J Anaesthesiol Clin Pharmacol. 2018;34(1):111–116 10.4103/joacp.JOACP_389_15. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Ye J, Ding H, Ren J, Xia Z. The publication trend of neuropathic pain in the world and China: a 20-years bibliometric analysis. J Headache Pain. 2018;19(1):110 10.1186/s10194-018-0941-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Wang X, Cao Y, Pang J, et al. Traditional Chinese herbal patch for short-term management of knee osteoarthritis: a randomized, double-blind, placebo-controlled trial. Evid Based Complement Alternat Med. 2012;2012:171706 10.1155/2012/171706. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Wang S, Guan J, Gong W, Bao B. Transdermal delivery of traditional Chinese medicine patch vs. NSAIDs patch for alleviating inflammation and relieving pain for early-stage knee osteoarthritis: a retrospective case control study. Front Pharmacol. 2025;16:1549883 10.3389/fphar.2025.1549883. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Meth. 1994;53(1):55–63 10.1016/0165-0270(94)90144-9. [DOI] [PubMed] [Google Scholar]
  • 20.Soliman N, Moisset X, Ferraro MC, et al. Pharmacotherapy and non-invasive neuromodulation for neuropathic pain: a systematic review and meta-analysis. Lancet Neurol. 2025;24(5):413–428 10.1016/S1474-4422(25)00068-7. [DOI] [PubMed] [Google Scholar]
  • 21.Quemeneur C, Guichard L, Martinez V. From data to decision: critical appraisal of the 2025 NeuPSIG review and recommendations on neuropathic pain treatments. Br J Anaesth. 2026;136(1):29–33 10.1016/j.bja.2025.10.005. [DOI] [PubMed] [Google Scholar]
  • 22.Meng J, Zhang Z, Wang Y, et al. The exploration of active components of 701 Dieda Zhentong patch and analgesic properties on chronic constriction injury rats. Purinergic Signal. 2025;21(4):593–609 10.1007/s11302-024-10056-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Yang HS, Mauki DH, Zheng YX, Wang TH, He XY. Terpenoids: a promising traditional Chinese medicine for neuropathic pain relief. Pharmacol Res. 2025;216:107789. [DOI] [PubMed] [Google Scholar]
  • 24.Wang P, Wen C, Olatunji OJ. Anti-inflammatory and antinociceptive effects of boesenbergia rotunda polyphenol extract in diabetic peripheral neuropathic rats. J Pain Res. 2022;15:779–788 10.2147/JPR.S359766. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Zhao Q, Zhang X, Long S, et al. Licochalcone mediates the pain relief by targeting the voltage-gated sodium channel. Mol Pharmacol. 2023;104(4):133–143 10.1124/molpharm.122.000658. [DOI] [PubMed] [Google Scholar]
  • 26.Wu Y, Chen J, Wang R. Puerarin suppresses TRPV1, calcitonin gene-related peptide and substance P to prevent paclitaxel-induced peripheral neuropathic pain in rats. Neuroreport. 2019;30(4):288–294 10.1097/WNR.0000000000001199. [DOI] [PubMed] [Google Scholar]
  • 27.Zhang C, Li Y, Yu Y, et al. Impact of inflammation and Treg cell regulation on neuropathic pain in spinal cord injury: mechanisms and therapeutic prospects. Front Immunol. 2024;15:1334828. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Huang M, Yang Y, Tang Y, Li Y, Wang X, Zhou M. RUNX1 induces central neuropathic pain by activating microglia and triggering the inflammatory response in spinal cord injury. Inflammation. 2025;48(6):4443–4460 10.1007/s10753-025-02336-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Yamasaki R, Fujii T, Wang B, et al. Allergic inflammation leads to neuropathic pain via glial cell activation. J Neurosci. 2016;36(47):11929–11945 10.1523/JNEUROSCI.1981-16.2016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Hirano T. IL-6 in inflammation, autoimmunity and cancer. Int Immunol. 2021;33(3):127–148. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Slowikowski K, Nguyen HN, Noss EH, et al. CUX1 and IκBζ (NFKBIZ) mediate the synergistic inflammatory response to TNF and IL-17A in stromal fibroblasts. Proc Natl Acad Sci USA. 2020;117(10):5532–5541 10.1073/pnas.1912702117. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Robert M, Miossec P. IL-17 in rheumatoid arthritis and precision medicine: from synovitis expression to circulating bioactive levels. Front Med. 2018;5:364 10.3389/fmed.2018.00364. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Jiang X, Zhou R, Zhang Y, Zhu T, Li Q, Zhang W. Interleukin-17 as a potential therapeutic target for chronic pain. Front Immunol. 2022;13:999407. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Jin B, Moududee SA, Ge D, et al. SCF(FBXW11) complex targets interleukin-17 receptor A for ubiquitin-proteasome-mediated degradation. Biomedicines. 2024;12(4):755 10.3390/biomedicines12040755. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Herjan T, Hong L, Bubenik J, et al. IL-17-receptor-associated adaptor Act1 directly stabilizes mRNAs to mediate IL-17 inflammatory signaling. Nat Immunol. 2018;19(4):354–365 10.1038/s41590-018-0071-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Neininger A, Kontoyiannis D, Kotlyarov A, et al. MK2 targets AU-rich elements and regulates biosynthesis of tumor necrosis factor and interleukin-6 independently at different post-transcriptional levels. J Biol Chem. 2002;277(5):3065–3068. [DOI] [PubMed] [Google Scholar]
  • 37.Burma NE, Leduc-Pessah H, Fan CY, Trang T. Animal models of chronic pain: advances and challenges for clinical translation. J Neurosci Res. 2017;95(6):1242–1256 10.1002/jnr.23768. [DOI] [PubMed] [Google Scholar]
  • 38.Percie du Sert N, Hurst V, Ahluwalia A, et al. The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. PLoS Biol. 2020;18(7):e3000410. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Todo H. Transdermal permeation of drugs in various animal species. Pharmaceutics. 2017;9(3):33. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

All data generated or analyzed during this study are included in this manuscript and its supplementary information flies.


Articles from Journal of Pain Research are provided here courtesy of Dove Press

RESOURCES